Logo for Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc Investor Relations Material

Latest events

Logo for Aldeyra Therapeutics Inc

R&D Day 2024

Aldeyra Therapeutics Inc
Logo for Aldeyra Therapeutics Inc

Q1 2024

2 May, 2024
Logo for Aldeyra Therapeutics Inc

R&D Day 2024

25 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Aldeyra Therapeutics Inc

Access all reports
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.